Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies by Frew, J.W. et al.
Defining Lesional, Perilesional and Unaffected Skin in Hidradenitis Suppurativa:  
Proposed Recommendations for Clinical Trials and Translational Research Studies 
 
JW Frew1, K Navrazhina1,2, A Byrd3 A Garg4, JR Ingram5, JS Kirby6, MA Lowes1, H Naik7, V 
Piguet8,9, EP Prens10 
 
 
1Laboratory of Investigative Dermatology, The Rockefeller University, NY, USA 
2 Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, Weill Cornell 
University, NY, USA 
3Department of Dermatology, Howard University, Washington DC, USA 
4Department of Dermatology, Hofstra Northwell School of Medicine, New Hyde Park, NY, USA 
5Institute of Infection & Immunity, Cardiff University, University Hospital of Wales, Cardiff, UK 
6Department of Dermatology, Penn State Hershey Medical Center, Hershey, PA, USA. 
7Department of Dermatology, University of California, San Francisco, USA 
8 Division of Dermatology, Women’s College Hospital, Toronto, Ontario, Canada 
9 Division of Dermatology, Dept of Medicine, University of Toronto, Toronto, Ontario, Canada 
10Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands 
 
 
 
Word Count: 631 
Figure Count: 1 
 
 
Corresponding Author: 
John W Frew 
Laboratory of Investigative Dermatology,  
The Rockefeller University 
1230 York Avenue 
New York, NY, United States of America 
Ph: +1-212-327-7153 
Fax: +1-212-327-8232 
Email: jfrew@rockefeller.edu 
 
 
Key Words: Hidradenitis Suppurativa, Biopsy, Clinical Trial, Guidelines, Lesion, Definition 
Main Text: 
Hidradenitis suppurativa (HS) is a chronic, recurring inflammatory skin condition for which the 
pathogenesis is not completely elucidated1. With the increase in HS-related research comes the 
need to enhance reproducibility, quality, accuracy and reproducibility of scientific methods. 
Unlike other inflammatory dermatoses such as psoriasis or atopic dermatitis, HS lesions are 
morphologically diverse and include nodules, abscesses, tunnels and fibrosis in various 
permutations and combinations admixed in the same anatomical region1. This makes general 
definitions as ‘lesional’ and ‘non-lesional’ insufficient for HS-related investigations. A definition 
for non-lesional skin is lacking. Accurate assessment of the pathophysiologic changes in HS 
lesions (and the response to therapeutics) requires standardized definitions of lesional, 
perilesional and unaffected skin biopsies. This is especially pertinent given the well-
characterized compartmentalization of cytokines in HS2, indicating that serum inflammatory 
markers may not accurately reflect the inflammatory mileu of lesional HS tissue. An additional 
complicating factor is the unique inflammatory environment of healthy axillae, groin and 
submammary folds with an increased IL-17 and innate immune signature3, which makes it 
crucial to ensure that unaffected skin samples are taken from a site that ensures an accurate 
comparison. For control specimens, or samples from healthy volunteers, the use of surgical 
discard from abdominoplasty is problematic given the unique immunological milieu of 
apocrine-rich (axillary, inguinal, submammary) skin3. The use of region-matched control tissue 
is vital to avoid overestimation of the relative change of Th17 and other innate immune 
markers. Ideally, healthy control skin should also be matched for other criteria such as age, 
gender, and ethnicity. 
 
Examination of the existing literature4 pertaining to inflammatory mediators in HS identified 
two high-quality studies with a priori definitions of biopsy sites5,6. Lesional skin was defined as 
the edge of an inflammatory lesion, perilesional as normal-appearing skin 2cm away from the 
inflammatory lesion, and unaffected skin as normal-appearing skin ≥10cm distant. An important 
caveat is that the reference lesion in these studies requires a priori definition. For the majority 
of published studies this was an inflammatory nodule. Biopsies for tunnels may require deeper 
full-dermal tissue sampling It is known that histologically fibrotic tissue attenuates the levels of 
inflammatory mediators compared with non-fibrotic tissue, and the invasive proliferative 
gelatinous mass (IPGM) of HS tunnels has a specific cytokine signature distinct from lesional 
tissue7. Therefore, classifying the reference lesion (nodule, tunnel, hypertrophic scar) is crucial 
for comparison across studies. The presence of dermal tunnels may introduce unintended 
pathology which can be difficult to appreciate clinically, and hence ultrasound is a useful non-
invasive assessment tool to identify dermal tunnels and deep abscesses in order to avoid 
inadvertent biopsy of a lesion in place of a control sample. 
 
In the context of clinical trials, assessment of lesional tissue is often an exploratory endpoint8 
given the lack of biomarkers in HS. While the data are not considered a primary or secondary 
endpoint, they do contribute to the existing knowledge of pathophysiology of disease. 
Therefore, based upon the existing literature (and the authors’ combined experience) we 
propose the following recommendations: (1) samples should be obtained from three sites: 
lesional, perilesional, and unaffected skin; (2) the definitions of lesional, perilesional and 
unaffected skin as presented in Figure 1; (3) the anatomic region of the lesion should be 
recorded; (4) the lesion morphology should be classified (e.g. inflammatory nodule, abscess, 
tunnel, etc.); and (5) unaffected skin of HS patients and control (taken from healthy volunteers) 
samples, should be region matched to lesional and perilesional samples (ie. Within the same 
anatomical region). In the absence of clear standards for HS tissue sampling, these 
recommendations seek to begin this process. Consensus among stakeholders is needed on a 
valid and reliable approach to tissue sampling, so that these strategies can be implemented in 
future studies. The next step is to create a coherent consensus and this work is underway.  
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Figure Legends:  
 
Figure 1: Biopsy Definition Recommendations for Hidradenitis Suppurativa 
